An Op-Ed from a staff member at the Center for Individualized Medicine, Noralane Lindor, M.D.   “I’d like to know what diseases I ...

http://youtu.be/vzKM8oyCsUg?t=43s Not one to shy from giving bold predictions, Google Chairman and Mayo Clinic Trustee Eric Schmidt sat down with Bloomberg TV to talk ...

Andrew Feldman, M.D., from the Hematopathology/Laboratory Medicine and Pathology at Mayo Clinic, is figuring out the best questions to “ask” T-cell lymphoma cells — ...

Article originally posted on Discovery's Edge. Genetic research first intrigued pharmacologist Richard Weinshilboum, M.D., of Mayo Clinic in Rochester, Minn., more than 30 years ago, when he began painstaking biochemistry techniques in his Pharmacogenomics Laboratory. As Dr. Weinshilboum's research team studied enzymes involved in eliminating neurotransmitters, they discovered a related enzyme, known as TPMT, that eliminated a particular type of toxicity from the body after drug therapy for certain leukemia patients. Because 1 in 300 children with leukemia had adverse reactions to the drug therapy, Dr. Weinshilboum was curious whether variations in enzyme levels based on each child's genes played a role in the side effects.

With lung cancer accounting for more cancer-related deaths each year than the next four leading cancer types combined, the need for earlier diagnosis and ...

Editor's Note: Article Originally Featured on NPR blog; Microbiome Program researcher Purna Kashyap, MBBS, contributed to this article. Looks like Harvard University scientists have given us another reason to walk past the cheese platter at holiday parties and reach for the carrot sticks instead: Your gut bacteria will thank you. Switching to a diet packed with meat and cheese — and very few carbohydrates — alters the trillions of microbes living in the gut, scientists report Wednesday in the journal Nature. The change happens quickly. Within two days, the types of microbes thriving in the gut shuffle around. And there are signs that some of these shifts might not be so good for your gut: One type of bacterium that flourishes under the meat-rich diet has been linked to inflammation and intestinal diseases in mice.

On Saturday, Dec. 7, the director of the new Mayo Clinic Biomedical Ethics Program, Richard Sharp, Ph.D., joined Mayo Clinic Radio for a discussion of ...

New Publication from Tamas Ordog, M.D., Program Leader of the Epigenomics Program   Motility and functional gastrointestinal disorders have high prevalence in the community, cause significant morbidity, and represent a major health care burden. Despite major advances in our understanding of the cellular and molecular basis of gastrointestinal neuromuscular functions, many of these diseases still defy mechanistic explanations. The biopsychosocial model underlying the current classification of functional gastrointestinal disorders recognizes and integrates the pathogenetic role of genetic, environmental, and psychosocial factors but has not been associated with specific molecular mechanisms.

    Mark your calendars for October 6-8, 2014 for the 3rd Annual Individualized Medicine Conference! The Conference will once again be ...

Not only is this year celebrating Thanksgiving and the first day of Hanukkah on the same day (aptly titled Thanksgivukkah), tomorrow is also the ...

Recent research has illustrated that the intestinal microbiome plays a major role in the development of Type 1 diabetes. Researchers at Mayo Clinic, funded by the Iacocca Foundation and a National Institutes of Health RO1 grant, demonstrated that gluten in the diet may in fact modify the intestinal microbiome, increasing incidences of Type 1 diabetes. The findings were published Nov. 13, in PLOS ONE. The researchers demonstrated that mice fed a gluten-free diet had a dramatically reduced incidence of Type 1 diabetes. These mice were non-obese diabetic mice, and the gluten-free diet protected the mice against Type 1 diabetes. When the researchers added gluten back into the mice diets, it reversed the protective effect the gluten free diet had provided, and there also was a measurable impact of the gluten on the bacterial flora of the mice that might be one way in which gluten could affect the risk for diabetes.  

A recent publication, featuring the Director of the Biomarker Discovery Program at the Center for Individualized Medicine at Mayo Clinic, George Vasmatzis, examining the role of ASCL1 in the neuroendocrine differentiation of lung adenocarcinoma. The clinical significance of neuroendocrine differentiation in lung adenocarcinoma, and the most appropriate biomarkers for this assessment, has long been debated. In the absence of a gold standard, investigators have most commonly used immunohistochemical staining of one or a combination of neuroendocrine markers, such as chromogranin, synaptophysin, neuron-specific enolase or neural cell adhesion molecule (CD56/NCAM) to assess the role of neuroendocrine differentiation in lung cancer survival. Notably, previous reports have not included ASCL1, despite the pivotal role this gene has in the development of neuroendocrine cells in the lung.